Adapting to a changing business environment, outlook for the new financial year is 7-10% organic growth
Statement by CEO Mauricio Graber: “We have delivered a solid financial performance despite a volatile macroeconomic and geopolitical environment. Organic growth reached 9%, EBIT margin b.s.i. 26.8%, and the free cash flow b.a.s.i. ended at EUR 172 million in line with our latest guidance.
Approvals from authorities across the globe bring infant formula closer to breast milk in more countries
New regulatory approvals of Chr. Hansen’s Human Milk Oligosaccharides for infant formula by authorities in Europe, USA, Canada and Israel are paving the way for more market entries and higher usage levels across the globe. The new regulatory wins add to recent approvals in important mark
Solid results in an uncertain macroeconomic environment
Statement by CEO Mauricio Graber: “The execution of our strategy to differentiate as a focused microbial and fermentation technology company continued to deliver solid results with 9% organic growth for the third quarter 2021/22, equal to 13% growth in EUR terms. Our inflation-driven pricing measures started to contribute positively during
Enabling customers to bring more health benefits to bottle-fed babies
Food Standards Australia New Zealand, FSANZ, has approved Chr. Hansen's 2'-FL human milk oligosaccharide for infant formula in Australia and New Zealand. 2'-FL HMO is the most abundant and most studied human oligosaccharide in breast milk, used in infant formula around the world since 2016.
“As one of the leading sup
To help producers meet consumer demands for plant-based products delivering on taste, nutrition and sustainability, Chr. Hansen has developed a range of VEGA™ Boost cultures, our newest addition to the VEGA™ Culture Kit
Chr. Hansen has extended its range of cultures for plant-based dairy alternatives and used them to create a breakthrough, dairy-free fava bean cream cheese that boasts sensa
A peer reviewed article by University of Bologna establishes bacillus-based probiotics as a promising strategy to help tackle the increasing problem of antibiotic resistance, while also reducing the incidence of post-weaning diarrhea in pigs by 30% and mortality in broilers by 6–8%.
A just published review of 131 scientific articles evaluates the effectiveness of Bacillus strains as probiot
Bioscience leader extends its VEGA™ portfolio with a fermentation-enabled solution to help keep plant-based meat alternatives safe and fresh
After launching the VEGA™ Culture Kit for dairy alternatives in 2021, Chr. Hansen is stepping into the meat alternatives arena with the VEGA™ SAFEPRO® range – a new offering designed to keep plant-based alternative proteins safe and fresh for longer. T
Largest data set to date highlights the wide distribution of natural concentrations of human milk oligosaccharides and confirms the safety of intake even at high concentrations
HMOs – important groups of carbohydrates in human breast milk – can, in some cases, be secreted in very high concentrations, and still be safe and well-tolerated by infants.
This is the conclusion of a new study b
Continued solid growth in Food Cultures & Enzymes driven by core segments and accelerated growth in Health & Nutrition; 2021/22 outlook adjusted in response to market volatility and accelerating inflationary pressure
Statement by CEO Mauricio Graber: “In a challenging environment, Chr. Hansen continued its strong growth trajectory, delivering 14% organic growth in the second quarter. Gr
Thomas Schäfer Executive Vice President & Chief Scientific Officer, and member of the Executive Board will step down as EVP and CSO of Chr. Hansen Holding A/S effective March 31, 2022. Thomas Schäfer has been with the company since November 2017.
Since Thomas started in Chr. Hansen four and a half years ago, he has brought significant scientific knowledge to the company and strengthened
Results from a global survey deployed in 16 countries around the world reflect a strong interest in learning more about probiotics among consumers worldwide.
Global bioscience company Chr. Hansen has been included on Corporate Knights' list for the past five years and ranks this year as no. 2 on the Global top 100 list
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
Boege Allé 10-12
DK-2970 Hoersholm
Denmark